1:23 PM
 | 
Apr 11, 2019
 |  BC Extra  |  Politics & Policy

Regulatory reprieve with Brexit delay

An EU-granted extension for Brexit means short-term clarity for biopharma companies expecting EMA or European Commission decisions before the new Oct. 31 deadline.

The U.K. had been scheduled to leave the union Friday.

At least seven companies are awaiting a CHMP opinion or EC action...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >